Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings

被引：0
|
作者：
Hiroki Koshimichi
Toru Ishibashi
Nao Kawaguchi
Chisako Sato
Akira Kawasaki
Toshihiro Wajima
机构：
[1] Shionogi & Co.,Project Management Department
[2] Ltd,Clinical Research Department
[3] Shionogi & Co.,Medical Science Department
[4] Ltd,undefined
[5] Shionogi & Co.,undefined
[6] Ltd,undefined
来源：
Clinical Drug Investigation | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1189 / 1196
页数：7
相关论文
共 50 条
  • [1] Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings
    Koshimichi, Hiroki
    Ishibashi, Toru
    Kawaguchi, Nao
    Sato, Chisako
    Kawasaki, Akira
    Wajima, Toshihiro
    [J]. CLINICAL DRUG INVESTIGATION, 2018, 38 (12) : 1189 - 1196
  • [2] Baloxavir marboxil. Influenza virus cap-dependent endonuclease (CEN) inhibitor, Anti-influenza agent
    Cole, P.
    [J]. DRUGS OF THE FUTURE, 2018, 43 (06) : 379 - 387
  • [3] Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects
    Kim, Yun
    Lee, Sangwon
    Kim, Yohan
    Jang, In-Jin
    Lee, SeungHwan
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (02): : 422 - 432
  • [4] T-705, A Novel Anti-Influenza Virus Compound - the Safety, Tolerability and Pharmacokinetics in Human
    Kobayashi, O.
    Noto, M.
    Sakurai, T.
    Iwamoto, A.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E299 - E299
  • [5] Phase I multiple dose study for pharmacokinetics, safety and tolerability of T0902611, a novel investigational anti-cytomegalovirus agent
    Buchanan, J
    Sanderson, B
    Giordano, H
    Petersen, K
    Wright, M
    Mills, M
    Levy, M
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1167 - 1167
  • [6] A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers
    Mallory, Raburn M.
    Ali, S. Omar
    Takas, Therese
    Kankam, Martin
    Dubovsky, Filip
    Tseng, Leo
    [J]. BIOLOGICALS, 2017, 50 : 81 - 86
  • [7] A phase I, randomized study to evaluate the safety, tolerability, and pharmacokinetics of mefunidone in healthy subjects
    Han, Mai
    Huo, Bishan
    Hu, Gaoyun
    Zhang, Xin
    Cui, Gang
    Wu, Wei
    Mi, Na
    Zhang, Shixi
    Jin, Jiangli
    Lu, Xing
    Wu, Bidong
    Xiao, Chunyan
    Wang, Jing
    Bian, Zheng
    Li, Jintong
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [8] A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects
    Gul, Ahmet
    Ulker, Sibel
    Senturk, Recep Selim
    Turk, Ugur Onsel
    Gurgun, Cemil
    Lavrovsky, Yan
    Samsonov, Mikhail
    Ozen, Sebnem
    Altinel, Serdar
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [9] A phase I study to investigate safety, tolerability and pharmacokinetics of MRZ-9547 in healthy subjects
    Mendes, P.
    Dersch, H.
    Katgely, B.
    [J]. MOVEMENT DISORDERS, 2014, 29 : S143 - S143
  • [10] Ostabolin-CTM:: A phase I trial to assess its safety, tolerability and pharmacokinetics in healthy older adults
    Barclay, C. L.
    Anderson, R.
    Champoux-Knott, L.
    Morelli, G.
    Morley, P.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S47 - S47
12345